|Bid||8.96 x 900|
|Ask||9.13 x 800|
|Day's range||8.46 - 9.46|
|52-week range||2.84 - 45.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.
Up nearly 400% in the last month alone, Longeveron (NASDAQ: LGVN) is doubtlessly one of the more volatile biotechs in the longevity space. Between its brief dalliance with meme stock traders in November and recent progress with regulatory authorities, plenty of people have made a lot of money on the stock. The key fact for investors to know about Longeveron is that it's a young biotech without any late-stage projects.
Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.